pepmg_

Study summary · research use only

Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update

Review · human · Nutrients · 2020 · DOI 10.3390/nu12051389 · PMID 32408706

Plain-language summary

Paraphrased from the published abstract below — not a verdict on whether anything works.

This review (species not specified; human dementia populations discussed) provides a critical update on studies of acetyl-L-carnitine (ALC) in dementia and other cognitive disorders. The authors note that a 2003 systematic review found insufficient evidence to support clinical use, while a meta-analysis from the same year reported a significant advantage for ALC on clinical scales and psychometric tests, and additional studies have since been published. The authors describe the role of ALC in dementia as still debated, discuss proposed underlying mechanisms including effects on cell membranes, cholinergic activity, mitochondrial energy metabolism, and the gut-liver-brain axis, and state that further studies with homogeneous samples and longitudinal assessment are needed before systematic clinical application.

Abstract

Several studies explored the effects of acetyl-L-carnitine (ALC) in dementia, suggesting a role in slowing down cognitive decline. Nevertheless, in 2003 a systematic review concluded there was insufficient evidence to recommend a clinical use, although a meta-analysis in the same year showed a significant advantage for ALC for clinical scales and psychometric tests. Since then, other studies have been published; however, a critical review is still lacking. We provide an update of the studies on ALC in primary and secondary dementia, highlighting the current limitations and translational implications. Overall, the role of ALC in dementia is still under debate. The underlying mechanisms may include restoring of cell membranes and synaptic functioning, enhancing cholinergic activity, promoting mitochondrial energy metabolism, protecting against toxins, and exerting neurotrophic effects. The effects of ALC on the gut-liver-brain axis seem to identify the category of patients in which the new insights contribute most to the mechanisms of action of ALC, likely being the liver metabolism and the improvement of hepatic detoxifying mechanisms the primary targets. In this framework, our research group has dealt with this topic, focusing on the ALC-related cross-talk mechanisms. Further studies with homogeneous sample and longitudinal assessment are needed before a systematic clinical application.

Read the full study on PubMed ↗ Open-access full text ↗

pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.